At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address major unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.
Our product portfolio includes the following:
- SUSTOL® (granisetron) extended-release injection is approved by the U.S. Food and Drug Administration (FDA) and is indicated in combination with other antiemetics in adults for the prevention of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.
- CINVANTI™ (HTX-019), also being developed for the prevention of CINV, has the potential to become the first polysorbate 80 free, intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist. We filed an NDA for CINVANTI (HTX-019) using the 505(b)(2) regulatory pathway in January 2017.
- HTX-011 is our long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. Targeting both pain and inflammation has allowed HTX-011 to demonstrate an advantage over current standard of care in multiple surgical models-bunionectomy, hernia repair and abdominoplasty (tummy tuck)-in Phase 2 studies.
SUSTOL and our investigational product candidates utilize our innovative science and technology platforms, including our proprietary Biochronomer® drug delivery technology, which can deliver therapeutic levels of a wide range of otherwise short-acting pharmacological agents over a period of days to weeks with a single injection.